SWITCHING FROM INFLIXIMAB ORIGINATOR TO A BIOSIMILAR DOES NOT AFFECT PHARMACOKINETICS, IMMUNOGENICITY AND EFFICACY IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE

被引：0
|
作者：
van Hoeve, Karen
Dreesen, Erwin
Hoffman, Ilse
Ferrante, Marc
Ann, Gils
Vermeire, Severine
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
879
引用
收藏
页码：S199 / S199
页数：1
相关论文
共 50 条
  • [1] Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease
    van Hoeve, K.
    Dreesen, E.
    Hoffman, I.
    Ferrante, M.
    Gils, A.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S313 - S314
  • [2] Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease
    van Hoeve, Karen
    Dreesen, Erwin
    Hoffman, Ilse
    Van Assche, Gert
    Ferrante, Marc
    Gils, Ann
    Vermeire, Severine
    THERAPEUTIC DRUG MONITORING, 2019, 41 (03) : 317 - 324
  • [3] Pharmacokinetics, pharmacodynamics, and immunogenicity of biosimilar infliximab in pediatric patients with inflammatory bowel disease
    Dipasquale, V.
    Alibrandi, A.
    Pellegrino, S.
    Ramistella, V.
    Romano, C.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1618 - I1618
  • [4] Pharmacokinetics and immunogenicity of Infliximab biosimilar in inflammatory bowel disease patients
    Guardiola, J.
    Rodriguez Alonso, L.
    Padulles, N.
    Santacana, E.
    Serra, K.
    Padulles, A.
    Ruiz-Cerulla, A.
    Gilabert, P.
    Arajol, C.
    Ibanez-Sanz, G.
    Camps, B.
    Colom, H.
    Bas, J.
    Morandeira, F.
    Sanchez, E.
    Orobitg, J.
    Rodriguez Moranta, F.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S441 - S441
  • [5] Clinical outcomes of switching from originator to biosimilar infliximab in inflammatory bowel disease
    Lin, M. C-P
    Fauzi, M. N. B. M.
    Subramaniam, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 149 - 150
  • [6] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Srinivasan, Ashish
    Haifer, Craig
    Thin, Lena
    MEDICAL JOURNAL OF AUSTRALIA, 2021, 215 (09) : 435 - 435
  • [7] Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab
    Lim, David
    Bandiera, Rhiannon
    Handsley, Elizabeth
    MEDICAL JOURNAL OF AUSTRALIA, 2021,
  • [8] Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful
    Gervais, Lisa
    McLean, Luke L.
    Wilson, Michelle L.
    Cameron, Carol
    Curtis, Lee
    Garrick, Vikki
    Armstrong, Kat
    Tayler, Rachel
    Henderson, Paul
    Hansen, Richard
    Chalmers, Iain
    Wilson, David C.
    Russell, Richard K.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2018, 67 (06): : 745 - 748
  • [9] COMPARISON OF EFFICACY AND SAFETY OF BIOSIMILAR INFLIXIMAB TO ORIGINATOR INFLIXIMAB IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
    Muhammed, R.
    Wong, T.
    Haller, W.
    Protheroe, S.
    Whyte, L.
    Bremner, R.
    GUT, 2016, 65 : A259 - A260
  • [10] Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel disease
    Muhammed, R.
    Whyte, L.
    Protheroe, S.
    Bremner, R.
    Haller, W.
    Wong, T.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S291 - S291
12345